An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™. (SMART)

This study has been completed.
Sponsor:
Collaborator:
Merck Serono S.A., Geneva
Information provided by (Responsible Party):
Merck KGaA
ClinicalTrials.gov Identifier:
NCT01108887
First received: April 21, 2010
Last updated: September 16, 2013
Last verified: September 2013

April 21, 2010
September 16, 2013
September 2009
January 2013   (final data collection date for primary outcome measure)
Adherence to treatment [ Time Frame: Baseline to 12 months of treatment ] [ Designated as safety issue: No ]
Proportion of expected number of injections completed during 12 months of treatment as captured by RebiSmart.
Same as current
Complete list of historical versions of study NCT01108887 on ClinicalTrials.gov Archive Site
  • Effectiveness and convenience of treatment [ Time Frame: Baseline to 12 months of treatment ] [ Designated as safety issue: No ]
    Overall evaluation of RebiSmart use based on Convenience Questionnaire; reasons for missed injections; proportion of subjects who prematurely terminated treatment and reasons why, proportion of subjects remaining disease-free, proportion of subjects relapse free; mean number of relapses
  • Safety of treatment [ Time Frame: Baseline to 12 months ] [ Designated as safety issue: Yes ]
    Recording of adverse reactions
Same as current
Not Provided
Not Provided
 
An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™.
Assessment of Adherence, Effectiveness & Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™.

RebiSmart™ is a device with an electronic injection log to monitoring adherence to therapy. Therefore RebiSmart is a tool for administering Rebif in multi-dose cartridges that may improve patient satisfaction and adherence to therapy. The objectives of this study are to evaluate adherence, effectiveness and convenience of treatment in subjects with relapsing multiple sclerosis (RMS) using RebiSmart to self-inject Rebif in a multi-dose cartridge.

This is an observational, international, multicenter study planned to be conducted in RMS subjects using the RebiSmart auto-injector at 300 sites in 15 countries across Europe. The participating countries are Austria, Belgium, Czech Republic, Denmark, Estonia, France, Germany, Hungary, Lithuania, Portugal, Slovakia, Sweden, Switzerland, the Netherlands and the United Kingdom. Subjects with RMS naïve to treatment or currently being treated with Rebif multi-dose injected by RebiSmart for no more than 6 weeks and meeting the eligibility criteria will receive Rebif 22 or 44 mcg subcutaneously three time a week. The dose of Rebif will be titrated during the initial four weeks of treatment. The planned observational period per subject is 12 months. The study visits comprises of: Baseline or Day 1 (Visit 1), Month 6 (Visit 2), and Month 12 (Visit 3).

OBJECTIVES

Primary objective:

  • To assess adherence to treatment in subjects with RMS using RebiSmart to self-inject Rebif in a multi-dose cartridge

Secondary objectives:

  • To assess effectiveness and convenience of treatment in subjects with RMS using RebiSmart to self-inject Rebif in a multi-dose cartridge.
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Subjects with RMS naïve to treatment or currently being treated with Rebif multi-dose injected by RebiSmart for no more than 6 weeks

Multiple Sclerosis, Relapsing-Remitting
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
912
January 2013
January 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males and female subjects between 18-65 years of age (only in Germany: Males and females between 12 - 65 years of age in order to follow national medical society guidelines)
  • Female subjects must be neither pregnant nor breast-feeding and must lack child-bearing potential as defined by either: a) Post-menopausal or surgically sterile, or b) Using a highly effective method of contraception for the duration of the study. This is defined as a method that results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly, and includes for instance implants, injectables, combined oral contraceptives, intra-uterine device (IUD), sexual abstinence or vasectomised partner
  • Subjects diagnosed with Relapsing MS according to the revised McDonald Criteria (2005)
  • MS-treatment naïve subjects or subjects treated with Rebif multi-dose injected by RebiSmart for no longer than 6 weeks prior to Baseline visit
  • Subjects that are able to self-inject with RebiSmart (in the opinion of the physician)
  • Subjects with Expanded Disability Status Scale (EDSS) score < 6 (inclusive) at Baseline
  • Signed informed consent (in countries where subject signature is not mandatory: subject must be given the patient information)

Exclusion Criteria:

  • Subjects experiencing a relapse within 30 days before Baseline
  • Subjects who have participated in other studies within 30 days before Baseline
  • Subjects who received any MS therapy within 6 months prior to study enrolment (e.g., other disease modifying drugs: immunomodulatory, immunosuppressive agents or combination therapy) with the exception of Rebif multi-dose injected by RebiSmart
  • Any visual or physical impairment that precludes the subject from self-injecting the treatment using the RebiSmart
  • Pregnancy and breast-feeding
  • Serious or acute heart disease such as uncontrolled cardiac dysrhythmias, uncontrolled angina pectoris, cardiomyopathy, or uncontrolled congestive heart failure
  • Current or past (within the last 2 years) history of alcohol or drug abuse
  • Have any contra-indications to treatment with interferon beta-1a according to Summary of Product Characteristics
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Netherlands
 
NCT01108887
EMR 701068-526
Not Provided
Merck KGaA
Merck KGaA
Merck Serono S.A., Geneva
Study Director: Medical Responsible Merck Serono, a division of Merck KGaA, Darmstadt, Germany
Merck KGaA
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP